Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Perindopril
Drug ID BADD_D01739
Description Perindopril is a nonsulfhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to perindoprilat, its active metabolite, following oral administration. Perindoprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Perindopril may be used to treat mild to moderate essential hypertension, mild to moderate congestive heart failure, and to reduce the cardiovascular risk of individuals with hypertension or post-myocardial infarction and stable coronary disease.
Indications and Usage For the treatment of mild to moderate essential hypertension, mild to moderate congestive heart failure, and to reduce the cardiovascular risk of individuals with hypertension or post-myocardial infarction and stable coronary disease.
Marketing Status approved
ATC Code C09AA04
DrugBank ID DB00790
KEGG ID D03753
MeSH ID D020913
PubChem ID 107807
TTD Drug ID D03KYG
NDC Product Code 65977-0019
UNII Y5GMK36KGY
Synonyms Perindopril | Pirindopril | S-9490 | S 9490 | S9490 | S 9490-3 | S 9490 3 | S 94903 | Perindopril Erbumine | Erbumine, Perindopril | Perstarium
Chemical Information
Molecular Formula C19H32N2O5
CAS Registry Number 82834-16-0
SMILES CCCC(C(=O)OCC)NC(C)C(=O)N1C2CCCCC2CC1C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Haematoma24.07.01.001--
Haematuria20.02.01.006; 21.10.01.018; 24.07.01.047--
Haemolytic anaemia01.06.03.002---
Hallucination19.10.04.003--
Headache17.14.01.001--
Hepatitis09.01.07.004---
Hyperhidrosis08.01.03.028; 23.02.03.004--
Hyperkalaemia14.05.03.001--
Hypertonia15.05.04.007; 17.05.02.001---
Hyponatraemia14.05.04.002--
Hypotension24.06.03.002--
Increased appetite08.01.09.027; 14.03.01.003---
Insomnia17.15.03.002; 19.02.01.002--
Leukopenia01.02.02.001---
Loss of consciousness17.02.04.004---
Malaise08.01.01.003--
Menstrual disorder21.01.01.004---
Migraine17.14.02.001; 24.03.05.003---
Muscle spasms15.05.03.004--
Myalgia15.05.02.001--
Myocardial infarction02.02.02.007; 24.04.04.009--
Nasopharyngitis11.01.13.002; 22.07.03.002---
Nausea07.01.07.001--
Neck pain15.03.04.009--
Nephrolithiasis20.04.01.002--
Nervous system disorder17.02.10.001---
Nervousness19.06.02.003---
Neutropenia01.02.03.004---
Oedema08.01.07.006; 14.05.06.010---
Oedema peripheral02.05.04.007; 08.01.07.007; 14.05.06.011--
The 3th Page    First    Pre   3 4 5 6    Next   Last    Total 6 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene